This is supported by studies that have shown evidence of detectable levels of tumour-associated autoantibodies in individuals prior to presenting with cancer, including p53 responses a median of 3.5 years prior to lung cancer imaging detection [5], and the detection of p53 and Her2 in prediagnostic breast cancer samples [6]. This evidence concerns the gene TP53 and breast cancer.